A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
Uveal melanoma (UM) is a rare subset of melanoma characterized by the presence of early initiating GNAQ/11 mutations, with downstream activation of the PKC, MAPK, and PI3Kα pathways. Activity has been observed with the PKC inhibitors sotrastaurin (AEB071) and darovasertib (IDE196) in patients with U...
Guardado en:
Autores principales: | Alexander N. Shoushtari, Shaheer Khan, Kimberly Komatsubara, Lynn Feun, Nicolas Acquavella, Shahnaz Singh-Kandah, Tiffany Negri, Alexandra Nesson, Kelly Abbate, Serge Cremers, Elgilda Musi, Grazia Ambrosini, Shing Lee, Gary K. Schwartz, Richard D. Carvajal |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca14021bac2d473688895d4925fe502f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani AJ, et al.
Publicado: (2020) -
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
por: Natalya V. Mazurina, et al.
Publicado: (2021) -
Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study
por: Qiong Wang, et al.
Publicado: (2021) -
Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
por: Tory Starzyk, MA, et al.
Publicado: (2022) -
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang DY, et al.
Publicado: (2021)